Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MNLO - Menlo Therapeutics Inc.

Previous close
1.35
1.350   100.000%

Share volume: 0
Last Updated: Fri 04 Sep 2020 10:00:00 PM CEST
Pharmaceuticals: Major: -0.03%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
17%
Profitability 9%
Dept financing 40%
Liquidity 39%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$1.35
P/E Ratio 
N/A
DAY RANGE
$1.35 - $1.35
EPS 
-$3.75
52 WEEK RANGE
$1.00 - $7.48
52 WEEK CHANGE
-$72.84
MARKET CAP 
226.383 M
YIELD 
N/A
SHARES OUTSTANDING 
167.691 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$159,359,943
AVERAGE 10 VOLUME 
$1,953,816
AVERAGE 30 VOLUME 
$1,926,222
Company detail
CEO: David Domzalski
Region: US
Website: http://menlotherapeutics.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Major
Sector: Health Technology

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Redwood City, CA.

Recent news